Returns–Not enough quarters yet
These returns are for its stock picks as disclosed on Form 13F: last quarter's holdings, valued at this quarter's prices. They miss trades within each quarter, short positions, options, bonds, cash and fees, so they aren't the returns its clients got.
Top holdings
At the end of June 30, 2026. Change is in shares since the quarter before.2
| Stock | Value | Share of portfolio | Change |
|---|---|---|---|
| CYTKCytokinetics, Inc | $83.5M | 34.5% | |
| ZBIOZenas Biopharma, Inc. | $60.6M | 25.1% | |
| KLRAKailera Therapeutics | $54.1M | 22.4% | New |
| Biohaven LtdCUSIP G1110E107 | $43.7M | 18.1% |
Best picks still held
How each current holding has done since the quarter it first appeared in its filings (up to six years back).
| Stock | Held since | Return since | Now worth |
|---|---|---|---|
| CYTKCytokinetics, Inc | December 31, 2025 | +34.1% | $83.5M |
| Biohaven LtdCUSIP G1110E107 | December 31, 2025 | +31.8% | $43.7M |
| ZBIOZenas Biopharma, Inc. | December 31, 2025 | −30.1% | $60.6M |
Sold off last quarter
- BCRXBiocryst Pharmaceuticals Inc was $36.6M
Quarter by quarter
| Quarter | Its picks | S&P 500 |
|---|---|---|
| June 30, 2026 | +31.0% | +14.8% |
| March 31, 2026 | −12.0% | −4.6% |
Sources
Every number on this page points here. Each one links to the public record.
- 1SEC EDGAR: Royalty Pharma Sub-Manager, LLC Form 13F filingshttps://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=2081668&type=13F-HR&dateb=&owner=include&count=40CIK 2081668
- 2SEC: 13F for the quarter ended June 30, 2026https://www.sec.gov/Archives/edgar/data/2081668/000208166826000018/Filed August 21, 2026 · accession 0002081668-26-000018